Targeting aggregation in the development of therapeutics for the treatment of Huntington’s disease and other polyglutamine repeat diseases

Author： Steffan Joan S   Thompson Leslie Michels  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.7, Iss.2, 2003-04, pp. : 201-213

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A review of the treatment options for Huntington’s disease

By Bonelli Raphael M   Hofmann Peter  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 767-776

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic Prospects for the Prevention of Neurodegeneration in Huntington's Disease and the Polyglutamine Repeat Disorders

By  

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 1, 2007-01 ,pp. : 99-106

Bentham Science Publishers

Access to resources Recommend Favorite

Neuroprotection in Huntington;s Disease

By  

Letters in Drug Design & Discovery, Vol. 2, Iss. 2, 2005-03 ,pp. : 143-147

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic strategies in Huntington’s disease

By Alberch Jordi   Canals Josep M   Pérez-Navarro Esther  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 4, 2003-04 ,pp. : 449-465

Informa Healthcare

Access to resources Recommend Favorite

Targeting aggregation of extended polyglutamine proteins

By  

Inpharma, Vol. 1, Iss. 1334, 2002-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite